LQD Update
04 September 2018

LQD Update

Lithium and quetiapine are two add-on therapies currently licenced and recommended for treatment resistant depression (TRD) and have been demonstrated to be significantly more effective than antidepressant monotherapy or placebo. However, these treatments are underutilised in clinical practice and present a dilemma for clinicians as neither has been established as being superior to the other...

Share: